Journal of Lipid Research
Patient-Oriented and Epidemiological ResearchReduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1
Cited by (0)
This work was supported by National Institutes of Health Grants R01-HL119828, P01-HL088093, P01-HL055798, R01-HL124174, and R01-HL086599 (Y.I.M., J.L.W., S.T.). Ionis Pharmaceuticals provided funding via a lab service contract to University of California San Diego to perform the apoC-III-lipoprotein assay measurements. S.T. and J.L.W. are co-inventors of and receive royalties from patents or patent applications owned by the University of California San Diego on oxidation-specific and other antibodies and apoC-III-lipoprotein assays. S.T. has a dual appointment at University of California San Diego and Ionis Pharmaceuticals, Inc. A.D. is a full-time employee of Akcea Therapeutics. J.L.W. has received honoraria for consulting for Ionis, CymaBay, Intercept, and Prometheus Pharmaceuticals. V.J.A. and Q.Y. are employees of Ionis Pharmaceuticals. The other authors report no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- CHD
coronary heart disease
- FCS
familial chylomicronemia syndrome
- HDL-C
HDL cholesterol
- IQR
interquartile range
- LDL-C
LDL cholesterol
- Lp(a)
lipoprotein (a)
- nonHDL-C
total cholesterol – HDL cholesterol
- RLU
relative light units
- TRL
triglyceride-rich lipoprotein
- VLDL-C
VLDL cholesterol
Abbreviations:
- 1
Guest editor for this article was Alan M. Fogelman, David Geffen School of Medicine at UCLA.